id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-307160-1vz0gw1w	Morais-Almeida, Mário	COVID-19, asthma, and biologic therapies: What we need to know	2020-05-16		.txt	text/plain	3561	160	41	Ongoing prospective cohort studies (SARP, NHLBI and others) provide a unique opportunity to examine the effects of COVID-19 on severe asthma and potential interactions with therapy, including inhaled and oral corticosteroids, as well as targeted treatment with biologics. It was believed that low eosinophil counts in peripheral blood would be related to the infection with the SARS-CoV-2 virus itself, and not necessarily an indicator that treatments which reduce eosinophil counts in patients with asthma would be associated with more severe COVID-19 disease. As in the placebo controlled trials with omalizumab, mepolizumab, benralizumab, reslizumab and dupilumab in asthmatic patients, no risk of increased infection susceptibility or immunosuppressive effect was reported to date and, in the case of omalizumab, there is a possible anti-infectious effect; hence we do not need to discontinue these treatments during the current pandemic.	./cache/cord-307160-1vz0gw1w.txt	./txt/cord-307160-1vz0gw1w.txt